AbbVie Inc.: management transactions · United States · SEC (Form 4)

About AbbVie Inc.

AbbVie Inc. is a U.S. biopharmaceutical company listed on the NYSE under the ticker ABBV, with headquarters in North Chicago, Illinois, United States. The company was created in 2013 through the separation of Abbott Laboratories’ research-based pharmaceutical business, which gives AbbVie a relatively recent corporate history but a long operating lineage in branded pharmaceuticals. For French-speaking investors, AbbVie is best understood as a large-cap healthcare name with a defensive earnings profile, a strong dividend orientation, and meaningful exposure to high-value specialty medicines. AbbVie’s business model is centered on global discovery, development, manufacturing, and commercialization of innovative medicines. The company reports a broad international footprint, serving patients in more than 170 countries and maintaining R&D and/or manufacturing operations in roughly 20 countries. Its strategy is built around a diversified portfolio across major therapeutic areas, primarily immunology, neuroscience, oncology, and aesthetics, with additional exposure to eye care in its reporting framework. This mix supports revenue diversification, although the company still depends heavily on a handful of blockbuster products. The core revenue drivers include Skyrizi and Rinvoq in immunology, which have become the main growth engines as Humira continues its post-exclusivity decline. In neuroscience, AbbVie markets Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta. In aesthetics, the portfolio includes Botox Cosmetic and Juvederm, while oncology is anchored by therapies such as Imbruvica, Venclexta, and Elahere. These brands give AbbVie a strong competitive position in several specialty categories with high barriers to entry, supported by a large commercial infrastructure and sustained R&D investment. Competitive dynamics remain shaped by the Humira transition, but AbbVie has so far shown an ability to offset that pressure through strong uptake of Skyrizi and Rinvoq. Recent financial updates for 2024 and 2025 showed robust operating momentum, with newer immunology assets carrying the group and management reaffirming a strong medium-term growth outlook. Recent company announcements also point to continued pipeline expansion through acquisitions such as Nimble Therapeutics and Capstan Therapeutics, alongside positive clinical and regulatory progress in multiple programs, including tavapadon. For investors tracking U.S.-listed healthcare equities on the NYSE/NASDAQ, AbbVie remains a high-quality large-cap pharmaceutical name with a balance of cash generation, pipeline optionality, and transition risk from legacy products.